U.S. markets closed

Lonza Group AG (LZAGY)

Other OTC - Other OTC Delayed Price. Currency in USD
46.18+0.33 (+0.72%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close45.85
Bid0.00 x 0
Ask0.00 x 0
Day's Range46.12 - 46.99
52 Week Range45.47 - 66.00
Avg. Volume87,480
Market Cap34.554B
Beta (5Y Monthly)0.57
PE Ratio (TTM)27.99
EPS (TTM)1.65
Earnings DateN/A
Forward Dividend & Yield0.39 (0.85%)
Ex-Dividend DateMay 09, 2023
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for LZAGY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Analyst Report: Merck KGaAMerck KGaA operates in three main segments: life sciences, performance materials, and healthcare. The life sciences segment (47% of 2022 sales) primarily provides laboratory consumables and services to researchers in academia and applied fields, including the biopharmaceutical industry. In the healthcare segment (35%), Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In its electronics segment (18%), the company offers specialty materials to manufacture a variety of products, such as semiconductors, flat-screen televisions, automobiles, and cosmetics. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Reuters

    UPDATE 2-Moderna to cut mRNA drug substance production at Lonza facility

    Moderna said on Tuesday it will cut production of mRNA drug substance for its COVID-19 vaccine at Lonza's facility in Switzerland this quarter as part of a plan to align manufacturing of the shots with lower post-pandemic demand. The U.S. company had said last week it was in talks with its partners that fill vials and syringes globally to downsize vaccine production. Such a move will help Moderna adjust to the sharp fall in demand for COVID vaccines as payers cut back orders for the shots, partly following the end of the public health emergency for the disease.

  • The Wall Street Journal

    Lonza CEO Pierre-Alain Ruffieux to Leave

    Lonza’s shares fell almost 7% on news the CEO would depart at the end of September, which RBC described as unexpected and was unlikely to provide the market with confidence heading into next month’s capital-markets day.

  • Reuters

    UPDATE 2-Swiss drug ingredient maker Lonza's CEO to leave

    Contract drug manufacturer Lonza's Chief Executive, Pierre-Alain Ruffieux, will leave the Swiss company by mutual agreement at the end of the month, it said on Monday. Lonza said its medium-term strategy and outlook would be discussed in detail at its coming capital markets day on Oct. 17 and that Chairman Albert Baehny will take on the CEO responsibilities until the appointment of a permanent successor to Ruffieux. Shares in Lonza, which makes drug ingredients for healthcare and biotech companies, lost 3.3% in premarket trade.